These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 16316746)
1. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Zanardi R; Smeraldi E Eur Neuropsychopharmacol; 2006 May; 16(4):281-7. PubMed ID: 16316746 [TBL] [Abstract][Full Text] [Related]
2. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. Smeraldi E J Affect Disord; 1998 Feb; 48(1):47-56. PubMed ID: 9495601 [TBL] [Abstract][Full Text] [Related]
3. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. Ravizza L J Psychopharmacol; 1999; 13(3):248-54. PubMed ID: 10512080 [TBL] [Abstract][Full Text] [Related]
4. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Olié JP; Spina E; Murray S; Yang R Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136 [TBL] [Abstract][Full Text] [Related]
5. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Amore M; Jori MC; Int Clin Psychopharmacol; 2001 Nov; 16(6):317-24. PubMed ID: 11712619 [TBL] [Abstract][Full Text] [Related]
6. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Cassano GB; Jori MC; Int Clin Psychopharmacol; 2002 Jan; 17(1):27-32. PubMed ID: 11800503 [TBL] [Abstract][Full Text] [Related]
8. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Boyer P; Lecrubier Y; Stalla-Bourdillon A; Fleurot O Neuropsychobiology; 1999; 39(1):25-32. PubMed ID: 9892856 [TBL] [Abstract][Full Text] [Related]
9. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Bersani G; Meco G; Denaro A; Liberati D; Colletti C; Nicolai R; Bersani FS; Koverech A Eur Neuropsychopharmacol; 2013 Oct; 23(10):1219-25. PubMed ID: 23428336 [TBL] [Abstract][Full Text] [Related]
10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR; J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Randløv C; Mehlsen J; Thomsen CF; Hedman C; von Fircks H; Winther K Phytomedicine; 2006 Mar; 13(4):215-21. PubMed ID: 16423519 [TBL] [Abstract][Full Text] [Related]
14. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Montgomery SA Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S9-15; discussion S16-7. PubMed ID: 12685917 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Tomassini V; Pozzilli C; Onesti E; Pasqualetti P; Marinelli F; Pisani A; Fieschi C J Neurol Sci; 2004 Mar; 218(1-2):103-8. PubMed ID: 14759641 [TBL] [Abstract][Full Text] [Related]
17. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. Barrett JE; Williams JW; Oxman TE; Frank E; Katon W; Sullivan M; Hegel MT; Cornell JE; Sengupta AS J Fam Pract; 2001 May; 50(5):405-12. PubMed ID: 11350703 [TBL] [Abstract][Full Text] [Related]
18. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448 [TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. DelBello MP; Chang K; Welge JA; Adler CM; Rana M; Howe M; Bryan H; Vogel D; Sampang S; Delgado SV; Sorter M; Strakowski SM Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387 [TBL] [Abstract][Full Text] [Related]